FG
BIIB icon

Fairman Group’s Biogen BIIB Stock Holding History

Fairman Group’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$648 Hold
3
– – ﹤0.01% 309
2026
Q1 		$550 Hold
3
– – ﹤0.01% 303
2025
Q4 		$528 Sell
3
-3
-50% -$490 ﹤0.01% 312
2025
Q3 		$840 Hold
6
– – ﹤0.01% 246
2025
Q2 		$754 Hold
6
– – ﹤0.01% 229
2025
Q1 		$918 Hold
6
– – ﹤0.01% 222
2024
Q4 		$918 Hold
6
– – ﹤0.01% 284
2024
Q3 		$1.16K Hold
6
– – ﹤0.01% 327
2024
Q2 		$1.39K Hold
6
– – ﹤0.01% 305
2024
Q1 		$1.29K Hold
6
– – ﹤0.01% 312
2023
Q4 		$1.55K Buy
+6
New +$1.47K ﹤0.01% 287

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fairman Group's BIIB Position: Q2 2026 in Review

Fairman Group held its Biogen (BIIB) position steady in Q2 2026 at 3 shares worth $648. The position accounts for ﹤0.01% of the portfolio, ranked #309.

Fairman Group first reported a position in BIIB in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.55K in Q4 2023. 1,045 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Fairman Group held 3 shares of Biogen worth $648 as of Q2 2026.
  • Fairman Group left its Biogen share count unchanged in Q2 2026.
  • Biogen made up ﹤0.01% of Fairman Group's portfolio in Q2 2026, its #309 holding.
  • Fairman Group first reported a position in Biogen in Q4 2023 and has held it in 11 quarters since.
  • Fairman Group's Biogen position peaked at $1.55K in Q4 2023.
  • 1,045 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Fairman Group's 13F filing for Q2 2026, filed 4 Aug 2026.